MPN Roundtable Year in Review: The Impact of New Data in Myelofibrosis on the Evolving Treatment Landscape
Release Date: February 05, 2020
Expiration Date: February 05, 2021
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity was previously presented as a webinar with live Q&A in January of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.
The community multidisciplinary healthcare provider seeking to improve competence and confidence in the utilization of approved JAK inhibitor therapy and increase their knowledge of emerging treatment options will benefit from this expert review of key data in myelofibrosis from 2019 by Drs. Bose and Mesa. Participants will also be enlightened by how this data can impact their current practice and gain confidence in their ability to communicate with patients to ensure they make informed treatment decisions.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists, nurses, and other allied healthcare professionals who provide care to patients with myelofibrosis.
Upon completion of this educational activity, participants should be able to:
- Discuss emerging evidence on the role of JAK inhibitor therapy for the treatment of myelofibrosis
- Select optimal treatment approaches for patients with myelofibrosis, based on current and emerging evidence on the role of JAK inhibitor therapy
- Identify new JAK inhibitor treatment options under investigation with potential to improve outcomes for patients with myelofibrosis
MPN Roundtable Year in Review: The Impact of New Data in Myelofibrosis on the Evolving Treatment Landscape - Prithviraj Bose, MD, and Ruben Mesa, MD
Instructions for Participation and Credit
This activity is eligible for credit through February 5, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Prithviraj Bose, MD
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Dr. Prithviraj Bose obtained his medical degree from the Calcutta Medical College at the University of Calcutta in Kolkata, India. He completed an internship in internal medicine at a University of Washington affiliate in Spokane, Washington, and residency at the Henry Ford Hospital in Detroit, Michigan, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma. He then went on to join the hematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, Virginia, where he was an Assistant Professor of Medicine and a member of the NCI-designated VCU Massey Cancer Center. Dr. Bose is currently an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center, Houston.
Dr. Bose has published more than 200 peer-reviewed journal articles, book chapters, and scientific meeting abstracts. His work has appeared in The New England Journal of Medicine, Cancer Cell, Blood, and Williams’ Hematology. Additionally, Dr. Bose has served as a peer-reviewer for multiple hematology and oncology journals, including The Lancet Oncology, JAMA Oncology, Blood, The Lancet Haematology, and others.
Dr. Bose’s major clinical and research focus is on MPNs. He works closely with Dr. Srdan Verstovsek and the two have authored many articles together in peer-reviewed journals and books and continue to do so. Dr. Bose is also heavily involved in clinical trial design for patients with MPNs, and in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis and polycythemia vera at MDACC. Dr. Bose represents MD Anderson on the MPN panel of the National Comprehensive Cancer Network.
Ruben Mesa, MD
Mays Cancer Center
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas
Dr. Ruben Mesa received his medical degree from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota. He completed his residency in internal medicine and his fellowship in hematology/medical oncology at Mayo. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in internal medicine and medical oncology. Dr. Mesa is the Director at the Mays Cancer Center, the newly named center at UT Health San Antonio MD Anderson Cancer Center. The Mays Cancer Center is one of only four National Cancer Institute-designated Cancer Centers in Texas. For almost 30 years the cancer center has had a deep focus on providing world-class cancer care, advancing cancer research and educating the next-generation of cancer care scientists and care providers.
Dr. Mesa’s own practice builds on his role as an international expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that often lead to leukemia. He has been involved in MPN research for more than 20 years. He led the development of National Comprehensive Cancer Network’s panel guidelines, the first U.S. guidelines on the diagnosis and treatment of myelofibrosis, polycythemia vera, and essential thrombocythemia. Dr. Mesa has been the principal investigator or co-principal investigator of more than 70 clinical trials. He was the major research leader contributing to the FDA’s approval of ruxolitinib for polycythemia vera and myelofibrosis. He is currently leading the investigation of several other drugs for these types of cancers.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit.
Universal Activity Number: 827-0000-20-007-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-007-118
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Prithviraj Bose has received honoraria related to formal advisory activities from Incyte Corporation, Celgene Corporation, CTI BioPharma Corp., and Kartos Therapeutics, Inc., as well as consultant fees from Incyte. He has received grant support related to research activities from Astellas Pharma US, Inc., Blueprint Medicines, Celgene, Constellation Pharmaceuticals, CTI BioPharma, Incyte, Kartos Therapeutics, NS Pharma, Inc., Pfizer Inc., and Promedior, Inc./p>
Dr. Ruben Mesa has received honoraria as a consultant from Astellas Pharma US, Inc., Novartis AG, and Samus Therapeutics, Inc. He has received grant support related to research activities from Celgene Corporation, CTI BioPharma Corp., Genentech, Inc., Incyte Corporation, and Promedior, Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Jami Craig, Project Manager, and Joan Meyer, RN, MHA, Executive Director, and Wilma Guerra, Program Director have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.